Skip to main content
. 2019 Nov 1;11:9321–9330. doi: 10.2147/CMAR.S223271

Table 3.

Univariate And Multivariate Analysis Of Prognostics Factors Affecting OS For Two Treatment Cohorts

Variables Univariate Analysis Multivariate Analysis
Numbers HR P value HR P value
Sex (Male vs Female) 114/11 0.645(0.322–1.293) 0.217
Age (≥56 vs <56) 64/61 0.759(0.491–1.173) 0.214
AFP level (≥400 ng/mL vs <400 ng/mL) 65/60 1.644(1.050–2.572) 0.030
HBV (Present vs Absent) 112/13 1.231(0.592–2.561) 0.578
Child Pugh Class (B vs A) 14/111 0.805(0.398–1.626) 0.545
Tumor size (≥5 cm vs <5 cm) 75/50 1.794(1.135–2.837) 0.012 1.732(1.086–2.760) 0.021
Number of lesions (Multiple vs Single) 108/17 1.676(0.807–3.481) 0.166
PVTT (Present vs Absent) 40/85 1.591(1.001–2.528) 0.050 2.297(1.379–3.827) 0.001
Distant metastasis (Present vs Absent) 71/54 1.580(1.005–2.485) 0.048 1.962(1.223–3.148) 0.005
Number of Previous TACE (>2 VS ≤2) 29/96 0.709(0.413–1.214) 0.210
Treatments (TACE-apatinib vs TACE) 42/83 0.459(0.274–0.770) 0.003 0.280(0.158–0.499) <0.001

Notes: Tumor size, PVTT, distant metastasis and treatments in this study were independent prognostic factors of OS.

Abbreviations: OS, overall survival; AFP, alpha-fetoprotein; HBV, Hepatitis B Virus; PVTT, portal vein tumor thrombus; BCLC, Barcelona Clinic Liver Cancer; TACE, transcatheter arterial chemoembolization.